PROTACs: A Paradigm Shift in Drug Discovery – Module 3
Released On
March 13, 2023
Expires On
March 12, 2024
Media Type
Internet
Completion Time
30 minutes
Specialty
Hematology-Oncology
Topic(s)
Leukemia, Lymphoma, Multiple Myeloma, Oncology, Pharmacology
This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.
The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of emerging data in the development of proteolysis targeting chimeras (PROTACs) that harness intracellular E3-ubiquitin ligases for the treatment of hematologic malignancies.
Learning Objective
Upon completion of this activity, participants should be better able to:
- Describe emerging proteolysis targeting chimeras (PROTACs) under investigation for the treatment of hematologic malignancies
Faculty
Katherine Donovan, PhD
Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Katherine Donovan, PhD, is a lead scientist in the Fischer Lab at the Dana Farber Cancer Institute in Boston, MA. She works on the development of molecular-glues and PROTAC molecules for targeted protein degradation. Dr Donovan completed her PhD training in protein biochemistry and structural biology at the University of Canterbury in New Zealand.
Dr Donovan developed an interest in proteomics as a specialized technology for quantifying protein-level expression changes in response to various perturbations. She set up and led proteomics teams focused on degrader screening and target identification in the Fischer Lab as well as in the Center for Protein Degradation. Dr Donovan has used proteomics technology to identify the degradation targets of many molecules, including the identification of SALL4 as the protein likely underlying the teratogenicity of thalidomide. She has led a large effort to map the degradable kinome and now, to aid her quest to map the degradable proteome, she has recently started a public degradation proteomics initiative that provides free target mapping of degraders. Dr Donovan continues to work on several projects related to ligase biology and protein degradation and also oversees the TPD proteomics operation in the Fischer Lab and Center for Protein Degradation.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Katherine Donovan, PhD, has relevant financial relationships with Kronos Bio, Neomorph Inc. (Consultant); Neomorph Inc. (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies.
Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Instructions for Participation and Credit
In order to receive credit, users must:
- Read the learning objectives and faculty disclosure
- Participate in the activity
- Complete the activity evaluation
A statement of credit will be available to print immediately.
There is no fee to participate.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
If you have questions about this activity, please contact RMEI at contact@rmei.com.